CN104881579B - One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique - Google Patents
One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique Download PDFInfo
- Publication number
- CN104881579B CN104881579B CN201510269325.4A CN201510269325A CN104881579B CN 104881579 B CN104881579 B CN 104881579B CN 201510269325 A CN201510269325 A CN 201510269325A CN 104881579 B CN104881579 B CN 104881579B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- traditional chinese
- epigastric pain
- medicine composition
- stagnation type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A kind of new screening technique for treating Qi-stagnation type epigastric pain Chinese medicine composition." effective prescription hypothesis " is proposed under traditional Chinese medicine theory guidance, with modern pharmacology method, for the Qi-stagnation type epigastric pain disease such as hydrochloric acid in gastric juice, stomachache, gasteremphraxis characteristic Design " pharmacological model screening system ", by the contribution degree evaluation method of " component contributions degree ", " comprehensive contribution degree ", new Chinese medicine composition is screened.For the present invention compared with Traditional Chinese Medicine medicine compatibility method, the composition and proportionate relationship of new compositions more clearly embody independence of each component in terms of Qi-stagnation type epigastric pain disease is treated and the contribution ability of collaboration.This screening technique step simple possible, new method is provided to find and studying the research of the compatibility theory of the new Chinese medicine composition of Qi-stagnation type epigastric pain and traditional prescription, and a kind of new screening thinking is provided to develop the pharmaceutical composition of other class diseases.
Description
Technical Field
The invention belongs to the technical field of biology and medicines, and particularly relates to a screening method of a traditional Chinese medicine composition for treating qi stagnation type epigastric pain, belonging to the technical field of biology and medicines.
The background art comprises the following steps:
the complexity, the multiple points of the action and the comprehensive coordination of the components in the traditional Chinese medicine prescription are consistent with the complexity characteristics of body diseases, and the characteristics of syndrome differentiation and treatment of the traditional Chinese medicine are reflected. The compatibility of traditional Chinese medicines is mainly based on empirical summary, and verification of modern scientific methods is lacked. Therefore, the establishment of a prescription screening method aiming at a complex system of body diseases scientifically clarifies the independent action and the comprehensive action of each component in the prescription, and the development of the research on the Chinese medicines of the components is a main task of the compatibility research of the Chinese medicines.
At present, most of new traditional Chinese medicine research ideas still take classical formulas and clinical experience formulas as bases, and new traditional Chinese medicines are developed through pharmacodynamic research, clinical trial research and the like.
With the development of advanced science and technology, basic research of drug effect substances of traditional Chinese medicines, research of action mechanisms, compatibility research, in vivo and vitro pharmacological research, clinical trial research and the like are widely developed, and the method plays an important role in promoting the modernization and standardization of traditional Chinese medicines. At present, the comparative research of single decoction and mixed decoction of the traditional Chinese medicine decoction tablet, the research of prescription removal and addition and subtraction optimization, the application of network pharmacological theory, the research method of bioavailability, the research method of serum medicine chemistry of the traditional Chinese medicine, the application of molecule knockout technology, the research of improving bioavailability by nanometer technology and the like are reported. However, the compatibility research of the traditional Chinese medicine does not form a set of simple and effective screening method.
The invention content is as follows:
the invention aims to provide a screening method of a traditional Chinese medicine composition for treating qi stagnation type epigastric pain, which is used for selecting a formula, improving the scientificity of compatibility and overcoming the defect of low screening precision of the traditional formula
The screening method of the invention comprises the following steps:
1. the theory of effective prescription is proposed according to the theory of traditional Chinese medicine, and each effective component in the prescription is determined. A modern pharmacological method is applied, a pharmacological model screening system is designed for gastric acid, stomachache, gastrectasia and other qi stagnation type epigastric pain symptoms, and a new traditional Chinese medicine composition is screened by evaluating the contribution degree of each component in the pharmacological model screening system.
2. The screening method of the traditional Chinese medicine composition comprises the following steps:
2.1. the hypothesis of an effective formulation is presented: according to the theory of traditional Chinese medicine, the prescription capable of treating qi stagnation type epigastric pain is designed by screening traditional classical prescriptions, or by document retrieval and statistical analysis, or by experimental research and the like, and an effective prescription hypothesis is provided.
2.2. Determining effective components: effective components in the effective prescription for treating qi stagnation type epigastric pain diseases are determined through known effective parts and experimental research results.
2.3. Preparing an effective component: the components with definite content and controllable quality are obtained by extraction and purification.
2.4. Establishing a pharmacological model screening system: according to the qi stagnation type epigastric pain disease symptoms, related pharmacological models are designed aiming at gastric acid, stomachache, gastrectasia and the like to form a pharmacological model screening system.
2.5. Obtaining pharmacological test data according to the test result of the effective components in the pharmacological model screening system;
2.6. evaluating the contribution degree of the effective components in a pharmacological model screening system according to a contribution degree evaluation method;
2.7. optimizing to generate the Chinese medicinal composition with definite component composition, definite component proportion and definite medicinal effect according to the comprehensive contribution degree of each component in the contribution degree evaluation result;
2.8. the systematic pharmacodynamics verification of the preferred traditional Chinese medicine composition for the qi stagnation type epigastric pain is carried out.
3. The contribution degree evaluation method comprises component contribution degree and comprehensive contribution degree, and the specific calculation and evaluation method comprises the following steps:
3.1. "degree of contribution of components": refers to the ability of the component to contribute to the effect of the test model, denoted by S.
Wherein:
x: administration group index results; m: and (5) model group index result.
3.2. "comprehensive contribution degree": means the comprehensive ability of the component to act on the pharmacological model screening system, and sigma is used S And (4) showing.
3.3. Evaluation of contribution degree:
aiming at the single model comparison of the 'component contribution degree', the action direction and the target point of each component are determined. Example S A >S B Indicating that the A component has higher ability than the B component when acting on the model;
comparing the comprehensive contribution degree of disease symptoms, and determining the action ability of each component on the symptoms, such as Sigma S A >∑S B It means that the A component has a higher ability to act on the disease symptom than the B component. And the traditional Chinese medicine composition for treating qi stagnation type epigastric pain is screened according to the proportion of the comprehensive contribution degree.
The effective prescription hypothesis is provided by screening the traditional classic prescriptions or by literature search and statistical analysis according to the traditional Chinese medicine theory and designing the prescription for treating qi stagnation type epigastric pain.
The effective components are extracted from each single traditional Chinese medicine in the effective prescription hypothesis, and the extract with definite process standard and quality standard is obtained by the steps of extracting, separating, purifying, concentrating, drying and the like, the fingerprint features of the extract are definite, and the content indexes of the effective components or the effective component groups are definite.
The pharmacological model screening system is composed of animal test models of gastric emptying, small intestine propulsion, analgesia, anti-inflammation and the like and pharmacological test methods of smooth muscle spasmolysis in vitro experiments and the like, and is used as a screening system of a new traditional Chinese medicine composition for qi stagnation type epigastric pain.
The new traditional Chinese medicine composition is obtained according to the screening step of the screening method 2, and is a traditional Chinese medicine composition with definite components and proportions for treating qi stagnation type epigastric pain diseases.
The invention has the positive effects that: aiming at the screening research of the new composition for treating qi stagnation type epigastric pain, a new drug composition screening method taking contribution degree evaluation as the core is established, so that a new effective composition is obtained, and a referable method is provided for screening new drug compositions for other diseases. The composition obtained by screening with the method is as follows: 5 parts of total saikosaponin: 3 parts of total saponins of white peony root: 4 parts of fructus aurantii volatile oil: 4 parts of nutgrass galingale rhizome volatile oil: 2 parts of rhizoma corydalis total alkaloids: 3 parts of licorice total flavonoids.
Claims (5)
1. A screening method of a traditional Chinese medicine composition for treating qi stagnation type epigastric pain is characterized by comprising the following steps: an effective prescription hypothesis is proposed according to the traditional Chinese medicine theory, effective components in the prescription are determined, a modern pharmacological method is applied, a pharmacological model screening system is designed aiming at qi stagnation type epigastric pain symptoms of gastric acid, stomachache or gastrectasia, and a new traditional Chinese medicine composition is screened by evaluating the contribution degree of each component in the pharmacological model screening system; comprises the following steps:
(1) An effective prescription hypothesis is put forward;
(2) Determining an effective component;
(3) Preparing an effective component;
(4) Establishing a pharmacological model screening system;
(5) Obtaining pharmacological test data in a pharmacological model screening system test through the effective components;
(6) Evaluating the contribution degree of the effective components in a pharmacological model screening system;
(7) Screening to obtain a composition according to the contribution degree evaluation result;
(8) The pharmacodynamics of the composition is verified, and a new traditional Chinese medicine composition is obtained;
the contribution degree comprises a component contribution degree and a comprehensive contribution degree, and is calculated according to the following method:
"degree of contribution of components": refers to the ability of the component to contribute to the action of the test model, denoted by S,
wherein: w = | X-M | X: administration group index results; m: model set index results;
∑ w ＝W 1 +W 2 +......+W n ；
"degree of comprehensive contribution": refers to the comprehensive ability of the component to act on a pharmacological model screening system, using sigma S It is shown that,
∑ s ＝S 1 +S 2 +......+S n 。
2. the screening method of the traditional Chinese medicine composition for treating qi stagnation type epigastric pain according to claim 1, is characterized in that: the effective prescription hypothesis is provided by screening the traditional classic prescriptions or by literature search and statistical analysis according to the traditional Chinese medicine theory and designing the prescription for treating qi stagnation type epigastric pain.
3. The screening method of the traditional Chinese medicine composition for treating qi stagnation type epigastric pain according to claim 2, is characterized in that: the effective components are extracts which are obtained by extracting, separating, purifying, concentrating and drying single traditional Chinese medicines in the effective prescription hypothesis and have definite process standards and quality standards, the fingerprint characteristics are definite, and the content indexes of the effective components or the effective component groups are definite.
4. The screening method of the traditional Chinese medicine composition for treating qi stagnation type epigastric pain according to claim 1, is characterized in that: the pharmacological model screening system is composed of an animal test model for gastric emptying, small intestine propulsion, analgesia and anti-inflammatory and an in-vitro experimental pharmacological test method for smooth muscle spasmolysis, and is used as a screening system for a novel traditional Chinese medicine composition for qi stagnation type epigastric pain.
5. The screening method of the traditional Chinese medicine composition for treating qi stagnation type epigastric pain according to claim 1, is characterized in that: the novel traditional Chinese medicine composition is a traditional Chinese medicine composition with definite components and proportion for treating qi stagnation type epigastric pain diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510269325.4A CN104881579B (en) | 2015-05-25 | 2015-05-25 | One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510269325.4A CN104881579B (en) | 2015-05-25 | 2015-05-25 | One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104881579A CN104881579A (en) | 2015-09-02 |
| CN104881579B true CN104881579B (en) | 2018-02-16 |
Family
ID=53949072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510269325.4A Active CN104881579B (en) | 2015-05-25 | 2015-05-25 | One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104881579B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105758950B (en) * | 2016-02-26 | 2018-02-06 | 辽宁中医药大学 | Qizhi weitong granules anti-inflammatory and antalgic method of quality control based on dose-effect colour atla |
| CN105758949B (en) * | 2016-02-26 | 2018-02-06 | 辽宁中医药大学 | Qizhi weitong granules based on dose-effect colour atla promotees gastroenteritic power method of quality control |
| CN105920112B (en) * | 2016-06-07 | 2019-11-26 | 浙江省中医院 | A kind of Chinese medicine composition and its application |
| CN112667922B (en) * | 2021-01-12 | 2022-06-28 | 山东大学 | Novel coronavirus traditional Chinese medicine formula recommendation method and system based on collaborative filtering |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1473583A (en) * | 2002-08-05 | 2004-02-11 | 浙江大学 | Researching and preparing method for new Chinese medicine |
| CN1899315A (en) * | 2005-07-22 | 2007-01-24 | 清华大学 | Developing method for Chinese medicine compound secondary new medicine |
| CN101190240A (en) * | 2006-11-22 | 2008-06-04 | 张贵君 | Component traditional Chinese medicine research approach and technology path |
| CN102445513A (en) * | 2011-09-22 | 2012-05-09 | 成龙 | A (Absorption)-M (Metabolization)-model-based traditional Chinese medicine new drug discovery policy and medicine and combination thereof |
| CN102652791A (en) * | 2011-07-25 | 2012-09-05 | 长春康彼达科技有限公司 | Medicinal composition with hepatic fibrosis resistance and preparation method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2773964A4 (en) * | 2011-11-03 | 2015-06-24 | Stc Biolog Inc | Method for determination of pharmacological properties of recombinant proteins |
-
2015
- 2015-05-25 CN CN201510269325.4A patent/CN104881579B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1473583A (en) * | 2002-08-05 | 2004-02-11 | 浙江大学 | Researching and preparing method for new Chinese medicine |
| CN1899315A (en) * | 2005-07-22 | 2007-01-24 | 清华大学 | Developing method for Chinese medicine compound secondary new medicine |
| CN101190240A (en) * | 2006-11-22 | 2008-06-04 | 张贵君 | Component traditional Chinese medicine research approach and technology path |
| CN102652791A (en) * | 2011-07-25 | 2012-09-05 | 长春康彼达科技有限公司 | Medicinal composition with hepatic fibrosis resistance and preparation method |
| CN102445513A (en) * | 2011-09-22 | 2012-05-09 | 成龙 | A (Absorption)-M (Metabolization)-model-based traditional Chinese medicine new drug discovery policy and medicine and combination thereof |
Non-Patent Citations (1)
| Title |
|---|
| 胃脘痛有效方药的筛选与评价;王为群;《中国博士学位论文全文数据库 医药卫生科技辑》;20090515(第5期);摘要,正文第4-5页第1.3.2-1.3.3小节,第6-7页第2.1小节,第11-12页第3.1小节,第46-51页第3.2小节,第52页第4.1小节,第63-64页第4.3-4.4小节,第77-79页第5.1-5.3小节,表3-1,3-21,3-22,5-1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104881579A (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chi et al. | Research progress on classical traditional Chinese medicine formula Lily Bulb and Rehmannia Decoction in the treatment of depression | |
| CN104881579B (en) | One kind treats Qi-stagnation type epigastric pain Chinese medicine composition screening technique | |
| Sun et al. | Immune-enhancing activity of polysaccharides isolated from Atractylodis macrocephalae Koidz | |
| Hu et al. | Traditional uses, origins, chemistry and pharmacology of Bombyx batryticatus: a review | |
| CN103933203B (en) | A kind of compound recipe Hematogenesis capsule being used for the treatment of aplastic anemia and preparation method thereof | |
| Zhao et al. | Text mining of rheumatoid arthritis and diabetes mellitus to understand the mechanisms of Chinese medicine in different diseases with same treatment | |
| US20170232035A1 (en) | Polygalacturonan Rhamnogalacturonan1 (PGRG1) Composition | |
| CN104288245B (en) | Anti-aging and constitutional pharmaceutical composition and preparation method thereof and detection method | |
| CN112107662B (en) | Traditional Chinese medicine composition for treating chronic gastritis and precancerous lesions of gastric cancer and medicament and application thereof | |
| CN110751981A (en) | Analysis method for explaining essence of traditional Chinese medicine syndrome based on system biology | |
| Qiao et al. | Herbal small RNAs in patients with COVID-19 linked to reduced DEG expression | |
| Xia et al. | Study on the Spectrum‐Effect Relationship of the Traditional Effect of Saponins in Glycyrrhiza uralensis Fisch | |
| Li et al. | Study on the effect of deep eutectic solvent liquid phase microextraction on quality standard, antitussive, and expectorant of sangbaipi decoction | |
| Oh et al. | The analysis of the recent research trend of Sipjeondabo-tang in Korea | |
| Yu et al. | Analysis of herbal mechanisms and prescriptions for chronic cerebral circulatory insufficiency based on data mining and network pharmacology | |
| Shi et al. | Zhichan decoction induces differentiation of dopaminergic neurons in Parkinson's disease rats after neural stem cell transplantation | |
| CN114487188A (en) | Metabonomics method for preparing animal model for treating primary dysmenorrhea based on radix aconiti kusnezoffii slices | |
| CN104069204B (en) | A kind of scutellaria decoction for treating ulcer colitis granule and preparation method thereof | |
| CN113012820A (en) | Identification method for key quality attributes of potential taste and flavor effects of traditional Chinese medicine preparation | |
| CN105287658A (en) | Application of medicine composition for preparing medicine for treating osteoporosis | |
| CN103301414B (en) | Gout, short kidney are arranged, repair kidney damages pharmaceutical composition and its preparation method and application | |
| Wang et al. | A Q-marker screening strategy based on ADME studies and systems biology for Chinese herbal medicine, taking Qianghuo Shengshi decoction in treating rheumatoid arthritis as an example | |
| Cai et al. | Autism spectrum disorder related tcm symptoms and tcm herbs prescriptions: a systematic review and meta-analysis | |
| CN106074643B (en) | Application of acanthopanax giraldii harms leaf and extract thereof in preparing anti-fatigue medicine or health food | |
| Yang et al. | Efficacy and safety of Qingfei Paidu decoction for patients with COVID-19: a systematic review and meta-analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gao Lu Inventor after: Su Ting Inventor before: Gao Lu |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190121 Address after: Room 607, Amendment Building, 1369 Shunda Road, Changchun High-tech Zone, Jilin Province, 130012 Patentee after: Jilin Modern Chinese Medicine Engineering Research Center Co., Ltd. Address before: 130103 No. 1369 Shunda Road, Changchun High-tech Zone, Jilin Province Patentee before: Changchun Kangbida Technology Co., Ltd. |
|
| TR01 | Transfer of patent right |